High potency vaccines induce protection against heterologous challenge with foot-and-mouth disease virus

被引：128

作者：

Brehm, K. E. ^{[1
]}

Kumar, N. ^{[1
]}

Thulke, H. -H. ^{[2
]}

Haas, B. ^{[1
]}

机构：

[1] Friedrich Loeffler Inst, Inst Diagnost Virol, D-17493 Greifswald, Germany

[2] UFZ Helmholz Ctr Environm Res, Dept Ecol Modelling, D-04318 Leipzig, Germany

来源：

VACCINE | 2008年 / 26卷 / 13期

关键词：

foot-and-mouth disease virus; protection by vaccines; serology;

D O I：

10.1016/j.vaccine.2008.01.038

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In a series of three homologous and eight heterologous challenge experiments, it was shown that high potency vaccines against foot-and-mouth disease (FMD) serotype A can induce protection even against heterologous challenge infection with viruses that give low r-values with the vaccine strains. The challenge virus specific neutralizing antibody response on the day of challenge (21 days post vaccination) generally correlated with protection. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：1681 / 1687

页数：7

共 26 条

[1]

AHL R, 1990, ALTERNATIVE POTENCY

[2]

ALONSO FA, 1987, B CENT PANAM FIEBRE, V53, P11

[3] Foot-and-mouth disease vaccine potency testing: determination and statistical validation of a model using a serological approach [J].

Barnett, PV ;

Statham, RJ ;

Vosloo, W ;

Haydon, DT .

VACCINE, 2003, 21 (23) :3240-3248

[4] The suitability of the 'emergency' foot-and-mouth disease antigens held by the International Vaccine Bank within a global context [J].

Barnett, PV ;

Samuel, AR ;

Statham, RJ .

VACCINE, 2001, 19 (15-16) :2107-2117

[5] Longevity of antibody and cytokine responses following vaccination with high potency emergency FMD vaccines [J].

Cox, SJ ;

Aggarwal, N ;

Statham, RJ ;

Barnett, PV .

VACCINE, 2003, 21 (13-14) :1336-1347

[6]

DOEL T, 2004, FMD VACCINE STRAIN S, P355

[7]

*EUR PHARM, 2006, FOOT MOUTH DIS RUM V

[8]

Ferris N P, 1992, Rev Sci Tech, V11, P657

[9] European Pharmacopoeia foot-and-mouth disease vaccine potency testing in cattle: Between test variability and its consequences [J].

Goris, N. ;

Merkelbach-Peters, P. ;

Diev, V. I. ;

Verloo, D. ;

Zakharov, V. M. ;

Kraft, H.-P. ;

De Clercq, K. .

VACCINE, 2007, 25 (17) :3373-3379

[10]

Karber G., 1931, ARCH EXP PATH PHARMA, V162, P480, DOI [DOI 10.1007/BF01863914, 10.1007/BF01863914]

← 1 2 3 →